18129-Lung Cancer-NA-1270

Lung Cancer

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Address

11750 W 2nd Place, Med Plaza 1, Suite 150
Lakewood, CO 80228
P: (303) 430-2700

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.